Nutex Health, Inc. is a technology-based healthcare services company. The company is headquartered in Houston, Texas.
| Revenue (TTM) | $796.53M |
| Gross Profit (TTM) | $408.79M |
| EBITDA | $449.62M |
| Operating Margin | 35.40% |
| Return on Equity | 47.60% |
| Return on Assets | 26.80% |
| Revenue/Share (TTM) | $114.28 |
| Book Value | $63.52 |
| Price-to-Book | 3.56 |
| Price-to-Sales (TTM) | 1.67 |
| EV/Revenue | 1.828 |
| EV/EBITDA | 4.03 |
| Quarterly Earnings Growth (YoY) | -26.40% |
| Quarterly Revenue Growth (YoY) | -18.70% |
| Shares Outstanding | $6.85M |
| Float | $4.15M |
| % Insiders | 29.23% |
| % Institutions | 45.44% |
Volatility is currently expanding
Nutex Health NASDAQ: NUTX reported lower third-quarter revenue and earnings despite a rise in hospital visits, as executives pointed to prior-year revenue adjustments tied to collections under the federal independent dispute resolution process.
HOUSTON, Nov. 5, 2026 /PRNewswire/ -- Nutex Health Inc. ("Nutex Health" or the "Company") (NASDAQ and Nasdaq Texas: NUTX), today announced financial results for the three and nine months ended September 30, 2026. Nutex Health is a physician-led, healthcare services and operations company with 28 hospital facilities in 12 states (hospital division), and a primary care-centric, risk-bearing population health management division.
Nutex Health's Q3 earnings face revenue pressure from reimbursement uncertainty, but rising patient volumes and lower arbitration costs may support profitability.
HOUSTON, Oct. 19, 2026 /PRNewswire/ -- Nutex Health, Inc. (NASDAQ: NUTX), a physician-led, integrated healthcare delivery system comprised of 28 state-of-the-art micro hospitals and hospital outpatient departments in 12 states and primary care-centric, risk-bearing physician networks, today announced that it plans to file its Form 10-Q for the third fiscal quarter ended Sept. 30, 2026, on Thursday, Nov. 5, 2026, after the market close.
Healthcare offers investors a potential combination of offense with forward earnings and defense with rising demand amid persistent macro-economic uncertainty. The healthcare sector is positioned for above-average long-term growth, supported by aging demographics, rising medical demand, and increased spending that's expected to outpace the broader economy. Strong forward revenue, EBITDA, and earnings growth demonstrate how select healthcare services and facilities companies can significantly outperform their sector peers.
Five stocks showing recent price strength include VNCE, VRA, AOUT, NUTX and FET, with strong momentum and improving earnings estimates.
Let's take a look at four stocks, NUTX, RCMT, TILE and QUAD, with impressive net profit margins for a robust portfolio.
Nutex Health is rated Strong Buy, with a new target price of $290.43, representing 39.1% upside from current levels. NUTX's profitability and growth metrics significantly outpace peers, driven by effective use of the No Surprises Act and disciplined cost controls. Consensus EPS projections for FY2026 and FY2027 have materially increased, with FY2026 EPS now expected at $27.79, supporting a forward PE of just 10.5.
EDRY, VNCE, NUTX, TXO and KB show strong recent price momentum despite a volatile September, backed by improving earnings expectations.
Nutex Health (NUTX) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on NUTX and any ticker you trade — then tracks every position and per-strategy win rate.
